Vivani Medical, Inc. filed an 8-K report detailing two key events: the approval of an Amended and Restated 2022 Omnibus Incentive Plan and the receipt of regulatory approval for a Phase 1 clinical trial. The Amended and Restated 2022 Omnibus Incentive Plan, approved by stockholders on June 24, 2026, increases the number of reserved shares of common stock by 11,000,000, bringing the total to 21,033,333 shares. The company also announced on June 25, 2026, that it received regulatory approval from Bellberry in Australia to initiate SLIM-1, a Phase 1 clinical trial for NPM-139, a semaglutide implant for obesity and chronic weight management. The SLIM-1 trial is expected to initiate in mid-2026 and will assess the safety, tolerability, and pharmacokinetics of NPM-139, with weight loss as a measured outcome. Vivani Medical is also preparing for SLIM-2, a potential dose-ranging efficacy trial for NPM-139, contingent on successful SLIM-1 results. The filing also includes the voting results from the Annual Meeting of Stockholders held on June 24, 2026, where directors were elected, executive compensation was approved on an advisory basis, the amended incentive plan was approved, and the appointment of BPM LLP as the independent registered public accounting firm was ratified.